The biotech firm reported a Q2 GAAP loss of $0.44 per share, beating estimates by $0.10, with $106.3 million in cash as of June 30, 2026.
Q32 Bio reported a Q2 GAAP loss of $0.44 per share, narrower than the expected loss by $0.10. The result reflects improved financial performance amid ongoing clinical development efforts.
The company held $106.3 million in cash and cash equivalents as of June 30, 2026. Proceeds from a July 2026 public offering are projected to extend its financial runway through Phase 3 topline results for its registration-directed program.
No immediate market reaction was disclosed in the release.